A Strategy to Deliver Precise Oral Doses of the Glucosinolates or Isothiocyanates from Moringa oleifera Leaves for Use in Clinical Studies.
Level 5 - mechanism / opinion, no new human data
Bench and food-science methodology study with no human clinical trial data
PubMed 31323988 · doi:10.3390/nu11071547
What was done
The authors developed and evaluated standardized protocols for preparing aqueous hot and cold infusions ("teas") from *Moringa oleifera* leaves to deliver calibrated oral doses of glucomoringin and its bioactive hydrolysis product, moringin, for use in future clinical trials.
What was found
The abstract reports no numerical values. Isothiocyanate yield from cold aqueous extraction was complete after 30 minutes, showing in vitro anti-inflammatory activity comparable to equimolar purified moringin. Both preparations were palatable without flavor masking and were reported safe regarding bacterial titers for up to 48 hours without refrigeration.
Why it matters
Standardized, low-cost delivery methods enable rigorous clinical testing of moringa's bioactive isothiocyanates, particularly in low-resource settings where the plant is cultivated.
Limits
This is strictly a laboratory preparation and feasibility study with no human pharmacokinetic, metabolic, or clinical outcome data. The abstract reports no exact numeric yields, concentrations, or microbial threshold measurements. Proposed therapeutic applications for diabetes, autism, and hypertension remain untested hypotheses.
Cited by
- supports The primary isothiocyanate found in moringa is moringin.